The Relation of Serum Bilirubin Level with the Severity and Complexity of Coronary Artery Disease and Long-term Outcomes in the Patients Undergoing Primary Percutaneous Coronary Intervention

Arsalan Salari¹ M.D., Fatemeh Moaddab² M.Sc., Mahsa Pourabdollah Tootkaboni¹ M.D., Maryam Shakiba³ Ph.D., Mohadeseh Poursadeghi¹* M.D.

¹Department of Cardiology, Guilan Interventional Cardiovascular Research Center, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran.
²Department of Nursing, Guilan Interventional Cardiovascular Research Center, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran.
³Department of Epidemiology, Guilan Interventional Cardiovascular Research Center, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran.

ABSTRACT

Background and aims: Bilirubin has been considered an antioxidant that protects against atherosclerosis. The aim of this study was to evaluate the relationship of serum bilirubin level with the severity and complexity of coronary artery disease (CAD) and long-term outcome in the patients undergoing primary percutaneous coronary intervention (PCI).

Materials and Methods: This prospective cohort study was performed on 136 patients with STEMI undergoing PCI in Heshmat Hospital, Rasht, Iran during 2 years. The complexity was calculated by using dedicated software of the syntax score and the severity of CAD was determined based on the number of vessel involvement. Also, long-term outcomes were evaluated by major adverse cardiac events (MACE) after one year.

Results: The mean total bilirubin level was 0.95 ± 0.69 mg/dl; 60.3% of the patients were in the low range of syntax score (0-22) and 38.2% had two vessels involved. In examining the relationship between serum bilirubin level with the severity and complexity of CAD and MACE, there was no statistically significant association (p>0.05); but, the majority of the patients with high bilirubin levels had a lower number of vessels involved and the complexity of the vessels; Also, MACE was observed in the patients with low bilirubin levels.

Conclusions: According to the results, attention to serum bilirubin level could be important in CAD and the protective effect of bilirubin can be used for new therapeutic decisions. Further studies on a larger sample of patients have been recommended to confirm and complete these findings.
Introduction

Coronary artery disease (CAD) is one of the most common causes of death worldwide. In 2010, about 7 out of total 53 million deaths were due to ischemic heart disease [1]. Heart muscle as an oxidative tissue and with constant activity is one of the tissues susceptible to oxidative damage caused by reactive oxygen species such as superoxide, hydrogen peroxide and hydroxyl [2]. Oxidative stress plays an important role in the pathogenesis of degenerative diseases or chronic such as atherosclerosis, diabetes and cancer [3, 4]. Oxidative stress as a result of an imbalance between the production of free radicals and reactive oxygen species on the one hand and the antioxidant defense system on the other hand. In other words, aerobic biological systems in order to cope with free radicals and reactive oxygen species, antioxidant defense mechanisms designed to neutralize the deleterious effects of these factors attacker, or to a minimum [4].

New scientific studies have suggested that bilirubin is a potential physiological antioxidant that can be an important protective role against atherosclerosis, CAD and inflammation take over [5]. Many factors increase the risk of CAD, including low serum bilirubin level, which is associated with increased risk of CAD [6]. Several studies have shown that bilirubin, the final product of hem metabolism has potent antioxidant capacity [7]. A study performed on healthy individuals. Dividing them according to serum bilirubin levels into 3 groups of low, intermediate and high, has shown that high bilirubin level prevents coronary flow reserve impairment, microvascular dysfunction and probably coronary atherosclerosis [8]. Epidemiologic studies have indicated that the total bilirubin level is inversely related to diabetes mellitus, hypotension, CAD and metabolic syndrome [9-12]. Atherosclerosis and inflammation are associated with free oxygen and peroxyl radicals’ formation [13, 14]. Arterial protective responses and adjustment against oxidative stress have important roles in atherosclerosis prevention [15]. Studies have shown that different forms of circulating bilirubin and its precursor, biliverdin, have the ability to remove the reactive forms of oxygen. They also prevent the oxidation of low-density-lipoprotein particles and monocyte chemotaxis all which are considered as stages of atherosclerosis [16-20]. Considering the high prevalence of CAD and impact of bilirubin level on severity of the disease and its consequences, this study was performed to assess bilirubin levels in the patients with STEMI who underwent primary percutaneous coronary intervention (PCI), its relation with the complexity and severity of coronary vessel involvement and to determine its long-term effects in such patients.

Materials and Methods

The study was performed as a prospective cohort on 168 patients with STEMI who underwent primary PCI in the Heshmat Hospital (Rasht, Iran) during 2 years. The patients with hepatocellular disorder (LFT ≥ 2
fold above the normal level), patients suffering from malignancy, those who had an alcohol abuse history and severe heart failure (EF ≤ 30%), acute coronary syndrome in past three months, kidney problem (creatinine > 2 mg/dl), erythrocyte diseases and connective tissue diseases were excluded from the study. After performing the exclusion criteria, 136 patients were registered. All the patients with diagnosis of STEMI, including: having chest-pain for more than 20 minutes, ST segment elevation of more than 1 mm in at least 2 adjacent leads on electrocardiography, or the patients with new LBBB, underwent primary PCI within 12 hours of the diagnosis.

All these patients received stat dose of 325 mg aspirin and 600 mg clopedrogril. Maintenance dose: 150 mg clopedrogril for one week, then 75 mg clopedrogril for the period of a month up to 1 year, according to their stent type [21]. Angiography was done by femoral approach and a dose of 5000 IU heparin was given to all patients before the procedure. Successful PCI was defined as <50% residual of in-segment stenosis. The angiography films were studied and the number of vessels with ≥50% involvement and minimum diameter of 1.5 mm was determined. Syntax score was calculated separately for each patient according to the software (http://syntax.score.com).

Total bilirubin level was measured by the standard method of photometry in the serum of all patients and then the patients were divided into two groups, according to their bilirubin levels: patients with high total bilirubin (>1 mg/dl) and the patients with a low level total level (≤ 1 mg/dl). Demographic information, including age, gender, body mass index (BMI), diabetes mellitus, and hypercholesterolemia were initially obtained in specified forms. All the patients were followed up after a year by making phone calls, free visits and echocardiography. Long-term outcomes were evaluated by major adverse cardiac events (MACE), including death and myocardial infarction (re-MI), stroke and stent thrombosis. Death count was determined by death due to cardiovascular etiologies or death with no specific cause. Stent thrombosis was defined as complete occlusion on angiography.

Re-MI was defined as creatine kinase-MB≥2 folds above the upper normal limit. ST-segment elevation and stroke were described as physical disability related to neurologic issues. This study was confirmed by the Ethics Committee of Guilan University of medical sciences research and technology assistance and informed consent forms were obtained from each patient.

**Statistical analysis**

After collecting, the data were analyzed by descriptive and inferential statistics (Kolmogorov-Smirnov, t-test, Chi-square test, Fisher exact test and logistic regression). P-value ≤ 0.05 was considered statistically significant.

**Results**

Demographic characteristics of the patients with a high total bilirubin level and low total bilirubin level are shown in table 1. The findings revealed that the average age of patients being studied was 58.71±13.13 years. The average bilirubin level was 0.95±0.69 mg/dl. Most of the patients were male (70.6%), with bilirubin levels of less
than 1 mg/dl (70.6%), left ventricular ejection fraction of 30-45% (50%), mild complexity of coronary vessels, with a syntax score of 0.22 (60.3%), two vessels disease (38.2%), did not suffer from diabetes mellitus (75%) and hypercholesterolemia (70.6%). After assessment of the relation between serum bilirubin level and demographic information associated with the disease, only left ventricular ejection fraction has a statistically significant relation with the serum total bilirubin level (p<0.03). Although no significant relation was observed between the severity of coronary vessel involvement, coronary vessel complexity and MACE, but the findings revealed that the majority of the patients with high serum total bilirubin levels had less number of coronary vessels involved (43.5% with one affected vessel) and less vessel complexity (syntax score 0-22 63.6%). MACEs did not occur in the patients with a high total bilirubin level, but were observed in 7.6% of the patients with a low total bilirubin level. In a regression logistic analysis (with Enter method) all demographic variables associated with the disease were analyzed. In this analysis, bilirubin level was not a predictive factor for any of the three variables: severity of coronary vessels involvement, complexity of coronary vessels and MACE; but BMI and left ventricular ejection fraction were known as predictive factors for severity of coronary vessels involvement, as well as hypercholesterolemia as a predictive factor for complexity of coronary vessels (Tables 2 and 3).

**Discussion**

Serum bilirubin level, as a potentially antioxidant endogenous compound, is related to a number of diseases associated with oxidative stress, including atherosclerosis cancer and neurodegenerative diseases [22]. This study was performed in order to determine the relation between serum bilirubin level with the complexity and severity of coronary vessels involvement and its long-term impacts on the patients suffering from STEMI underwent PCI. This study is among the few studies, which have explored the relation between total bilirubin levels and MACE, one year after PCI, and also its relation with complexity of vessels in the patients suffering from Acute STEMI. No statistical significant was observed in the present study during exploring the relation between severity of coronary vessel involvement and total bilirubin level, but most patients with high serum bilirubin level had less affected vessels. In this regard, the results of study conducted by Einollahi et al, revealed that the importance of measuring serum bilirubin levels as a predictor of coronary vessel disease, had no significant difference in verge, total bilirubin amount between the affected and the healthy groups, although a mild reverse relation between serum bilirubin and total bilirubin levels was observed [22], which were congruent with the results of the present study in a study conducted by Sadeghi et al. to evaluate the relation between serum bilirubin levels with coronary diseases based on angiographic findings, a significant difference was observed between verge total bilirubin
levels in two groups: patients with normal angiography and patients with 3 vessels involved. A reverse relation was observed in this study between total bilirubin levels, number of vessels affected the severity of stenosis and type of coronary vessel [23]. In a study conducted by Ghem et al. the average bilirubin level was higher in the control group as well. And bilirubin level reduction was related to severity and more prevalence of coronary vessel disease [15].

<table>
<thead>
<tr>
<th>Variables</th>
<th>Low bilirubin N (%)</th>
<th>High bilirubin N (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>26 (28.9)</td>
<td>14 (30.4)</td>
<td>Chi-square 0.85</td>
</tr>
<tr>
<td>Male</td>
<td>64 (71.1)</td>
<td>32 (69.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Age (Mean±SD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>59.55±13.28</td>
<td>57.04±12.97</td>
<td>t-test 0.29</td>
<td></td>
</tr>
<tr>
<td><strong>BMI (Mean±SD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26.74±5.19</td>
<td>26.42±3.73</td>
<td>t-test 0.73</td>
<td></td>
</tr>
<tr>
<td><strong>Hypercholesterolemia</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>30 (33.3)</td>
<td>10 (21.7)</td>
<td>Chi-square 0.16</td>
</tr>
<tr>
<td>No</td>
<td>60 (66.7)</td>
<td>36 (78.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes mellitus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>20 (22.2)</td>
<td>14 (30.4)</td>
<td>Chi-square 0.29</td>
</tr>
<tr>
<td>No</td>
<td>70 (77.8)</td>
<td>32 (69.6)</td>
<td></td>
</tr>
<tr>
<td><strong>LVEF</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than 30</td>
<td>10 (11.1)</td>
<td>2 (4.3)</td>
<td>Chi-square 0.03* 0.17</td>
</tr>
<tr>
<td>30-45</td>
<td>38 (42.2)</td>
<td>30 (65.2)</td>
<td></td>
</tr>
<tr>
<td>More than 45</td>
<td>42 (46.7)</td>
<td>14 (30.4)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of involved vessels</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>28 (31.1)</td>
<td>20 (43.5)</td>
<td>Chi-square 0.17</td>
</tr>
<tr>
<td>2</td>
<td>34 (37.8)</td>
<td>18 (39.1)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>28 (31.1)</td>
<td>8 (17.4)</td>
<td></td>
</tr>
<tr>
<td><strong>Complexity of coronary vessel</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-22</td>
<td>54 (60)</td>
<td>28 (63.6)</td>
<td>Fisher exact test 0.53</td>
</tr>
<tr>
<td>22.1-32</td>
<td>32 (35.6)</td>
<td>16 (36.4)</td>
<td></td>
</tr>
<tr>
<td>More than 32</td>
<td>4 (4.4)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>MACE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6 (6.7)</td>
<td>0</td>
<td>Chi-square 0.09</td>
</tr>
<tr>
<td>No</td>
<td>84 (93.3)</td>
<td>46 (100)</td>
<td></td>
</tr>
</tbody>
</table>

*Significance level: P-value≤0.05; LVEF=Left ventricle ejection fraction; BMI=Body mass index
Table 2. Regression coefficients of severity of coronary vessels involvement predictors by Enter method

<table>
<thead>
<tr>
<th>Predictors</th>
<th>B</th>
<th>SE</th>
<th>OR</th>
<th>95% Confidence Interval of OR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Min</td>
<td>Max</td>
<td></td>
<td>Min</td>
<td>Max</td>
</tr>
<tr>
<td>LVEF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than 30</td>
<td>-21.96</td>
<td>1.63</td>
<td>0.001</td>
<td>0.001</td>
<td>0.99</td>
</tr>
<tr>
<td>30-45</td>
<td>-2.19</td>
<td>0.64</td>
<td>0.11</td>
<td>0.03</td>
<td>0.39</td>
</tr>
<tr>
<td>More than 45</td>
<td>Reference</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>BMI</td>
<td>0.13</td>
<td>0.07</td>
<td>1.14</td>
<td>0.99</td>
<td>1.029</td>
</tr>
</tbody>
</table>

*Significance level: P-value ≤ 0.05; LVEF = Left ventricle ejection fraction; BMI = Body mass index

Table 3. Regression coefficients of complexity of coronary vessels predictors by Enter method

<table>
<thead>
<tr>
<th>Predictors</th>
<th>B</th>
<th>SE</th>
<th>OR</th>
<th>95% Confidence Interval of OR</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Min</td>
<td>Max</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>Yes</td>
<td>-1.37</td>
<td>0.69</td>
<td>0.25</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>Reference</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Significance level: P-value ≤ 0.05

Likewise, in the present study, in the regression model, total bilirubin level was not known as a predictor for severity of coronary disease. In this regard, the results of Einollahi et al. study revealed bilirubin measurement can be important as a predictive index for CAD incidents [22]. Also, in the study conducted by Ghem et al., bilirubin was known as a new predictive marker for CAD [15]. Also, Erdogan et al. showed that high levels of bilirubin can serve as a predictive factor for CAD [24]. These findings are different from the results of the present study.

While studying the relation between coronary vessel complexity (according to syntax score) and serum total bilirubin level, no significant relation was found, but most patients with bilirubin levels had less complexity of the vessels. Also, total bilirubin level was not known as a predictor for complexity of coronary vessels in the regression model. In this regard, the results of a study conducted by Sahin et al. on NSTEMI patients revealed that total bilirubin level was significantly higher in the group with a high syntax score, and a significant relation was observed between total bilirubin level and syntax score [25], which incongruent with the results of the present study. This incongruity may be justified by the difference in studying the patients group. In Turfan et al. study aligned with results of the present study, total bilirubin level in the group with a low Syntax score was significantly higher than other groups, and total bilirubin was known as an independent predictor for syntax score [26]. Also, in Nabatchian et al. study the results showed that measuring bilirubin as a marker for the prediction of CAD is important [5]. No significant relation was observed in reviewing the relation of MACE with serum bilirubin level.
total bilirubin level, but no major cardiac events were seen in the patients with high bilirubin levels, but were observed in the patients with low bilirubin level. Total bilirubin was not known as a predictor for MACE as well. In this regard, in Sahin et al. study no significant relation was observed between the numbers of cardiac events in two groups with high and low bilirubin levels [25], which is congruent with the results of the present study. In contrast to the findings of this study, the results of Gul et al. revealed that number of hospital events was significantly higher in the group with high total bilirubin compared to the group with low total bilirubin. In regression analysis, it was observed a relation between high total bilirubin level and major hospital events. Total bilirubin was known as predictor for hospital events, but no significant relation was found between total bilirubin level and long-term outcomes [27]. In other study, it has been shown that total levels of bilirubin have a prognostic association with MACE in male patients with myocardial infarction [28].

One of the limitations of the present study was low number of the patients. It’s recommended that larger studies using more samples and more extensive clinical/laboratory parameters be conducted. That may lead to the bilirubin levels considered as a treatment goal as well as an index for determining CAD severity and controlling hospital events. Also, new markers for cardiovascular risk factor identification, predicting cardio vascular diseases and controlling outcomes could be identified; performing more studies is also recommended for confirming the results of the present study.

Conclusions

Although total bilirubin level in the present study was not known as a predictive factor for complexity and severity of coronary vessel involvement and MACE, but the results revealed that taking bilirubin levels under consideration according to less number of affected vessels, complexity of vessels and major hospital events in patience with higher bilirubin levels can be important. This predictive impact of bilirubin can be applied to new treatment plans. Furthermore, other factors such as, left ventricle ejection faction, BMI and hypercholesterolemia are known as predictors of complexity and severity of coronary vessel involvement and MACE; planning the treatment and preventive interventions accordingly can be helpful for the patients.

Conflict of Interest

None declared.

Acknowledgments

We acknowledge the directors and personnel of the Heshmat Hospital, Guilan, Iran.

References


[3]. Karajibani M, Montazerifar F, Hashemi M, Bolouri A, Dikshit M. Study of oxidative stress in...
patients with angina pectoris admitted to cardia
care unit (CCU) at khatam-al-Anbia hospital in
zahedan. Zahedan Journal of Research in Medical
[4]. Steghamati A, Zarban A, Doosti M. Evaluation of
antioxidant status and oxidative stress index in
patients with Type II diabetes mellitus. Iran J
[5]. Nabatchian F, Einollahi N, Boroomand MA,
Abbasi S. Can bilirubin be an indicator for
predicting coronary artery disease? Payavarde
Salamat 2014; 7(2): 91-100.
[6]. Lingenhel A, Kolleritis B, Schwager JP, Hunt
SC, Gress R, Hopkins PN, et al. Serum bilirubin
levels, UGT1A1 polymorphisms and risk for
coronary artery disease. Exp Gerontol J. 2008;
[7]. Stocker R, Glazer AN, Ames BN. Antioxidant
activity of albumin-bound bilirubin. Proceedings of
the National Academy of sciences of the United
States of America 1987; 84: 5918-922.
[8]. Gullu H, Erdogan D, Tok D, Topcu S, Caliskan
M, Ulus T, et al. High serum bilirubin
concentrations preserve coronary flow reserve and
coronary microvascular functions. Arterioscler
[9]. Hopkins PN, Wu LL, Hunt SC, James BC,
Vincent GM, Williams RR. Higher serum bilirubin
is associated with decreased risk for early familial
coronary artery disease. Arterioscler Thromb Vasc
[10]. Han SS, Na KY, Chae DW, Kim YS, Kim S,
Chin HJ. High serum bilirubin is associated with
the reduced risk of diabetes mellitus and diabetic
nephropathy. Tohoku J Exper Med. 2010; 221(2):
133-40.
[11]. Chin HJ, Song YR, Kim HS, Park M, Yoon HJ,
Na KY, et al. The bilirubin level is negatively
related to the incidence of hypertension in
normotensive Korean population. J Korean Med
A, Girerd X, et al. Plasma bilirubin and
gamma-glutamyltransferase activity are
inversely related in dyslipidemic patients with
metabolic syndrome: relevance to oxidative stress.
[13]. Hansson GK, Robertson AK, Soderberg-Naucler
C. Inflammation and atherosclerosis. Annu Rev
[14]. Berliner JA, Navab M, Fogelman AM.
Atherosclerosis: basic mechanisms. Oxidation,
inflammation, and genetics. Circulation 1995;
91(9): 2488-496.
[15]. Ghem C, Sarmento-Leite RE, de Quadros AS,
Rossetto S, Gottschall C. Serum bilirubin
concentration in patients with an established coronary
[16]. Neuzil J, Stocker R. Free and albumin-bound
bilirubin are efficient co-antioxidants for alpha-
tocopherol, inhibiting plasma and low density
269(24): 16712-6719.
[17]. Mayer M. Association of serum bilirubin
concentration with risk of coronary artery disease.
[18]. Nakayama M, Takahashi K, Komaru T. Increased
expression of hemooxygenase-1 and bilirubin
accumulation in foam cells of rabbit atherosclerotic
lesions. Arteriosclerosis, Thrombosis, and Vascular
[19]. Stocker R. Antioxidant activities of bile
pigments. Antioxidants and Redox Signaling 2004;
6(5): 841-49.
[20]. Rigato I, Ostrow JD, Tiribelli C, Bilirubin and
the risk of common non-hepatic diseases. Trends
[21]. Braunwald E, Zipes DP, Libby P, Bonow R.
Braunwald's Heart Disease: A text book of
Cardiovascular Medicine. Vol 2. 7th. Philadelphia:
[22]. Einollahi N, Boroomand MA, Nabatchian F,
Abbasi S. The importance of measuring the
concentration of serum bilirubin as a marker for
predicting coronary artery disease. J Lab
[23]. Taban Sadeghi MR, Golmohamadi A, Parviz
R, Kezerlou Aghdam N, Sepharah A, Hosnavi Z.
The Relation of Serum Bilirubin Level with Coronary
Artery Disease Based on Angiographic Findings.
[24]. Erdogan T, Cicek Y, Kocaman SA. Increased
serum bilirubin level is related to good collateral
development in patients with chronic total coronary
[25]. Sahin O, Akpek M, Karadavut S, Cosgun MS,
Savas G, Sarli B, et al. Relation between Serum
Total bilirubin Levels and Severity of Coronary
Artery Disease in Patients with Non ST Elevation
Myocardial Infarction. J Am College Cardiol.
[26]. Turfan M, Duran M, Poyraz F, Yayla C, Akboga
between serum total bilirubin levels and severity of
disease in patients with stable coronary artery
disease. Coronary Artery Disease 2013, 24(1):
29-32.
[27]. Gul M, Uyarel H, Ergelen M, Akgul O, Karaca
G, Turen S, et al. Prognostic value of total bilirubin
in patients with ST-segment elevation acute
myocardial infarction undergoing primary
166-71.
[28]. Baumann S, Huseynov A, Koepp J, Jabbour C,
Behnes M, Becher T, et al. Comparison of serum
uric acid, bilirubin, and C-reactive protein as
prognostic biomarkers of in-hospital MACE
between women and men with ST-segment
elevation myocardial infarction. Angiology 2016;
67(3): 272-80.